drugset
drugset / Trial / NCT04661020

CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

NCT04661020 ↗

Phase 2 Recruiting 40 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

A Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

Timeline

Start
2020-12-03
Primary completion
2026-12-20
Completion
2026-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19 CAR-T cells Cell therapy — Intravenous

Indications

large B-cell lymphoma